Search

A new report discusses research findings on cell therapy for cancer treatment. The study focuses on targeting the membrane-proximal C2-set domain of CD33 to improve CAR T cell therapy. The researchers found that decreasing the distance between T cells and leukemia cells' membranes increased the efficacy of CD33 chimeric antigen receptor (CAR) T cells. The study demonstrated improved efficacy with CAR T cells binding CD33 close to the cell membrane, suggesting the potential for further investigation and possible clinical application. The research was conducted at the Fred Hutchinson Cancer Research Center in Seattle, Washington. [Extracted from the article]

A recent report from the University of Sydney discusses the use of histone methylation mark analyses to distinguish chimeric antigen receptor-modified T cell (CART) therapy products manufactured from different sources. The researchers found that histone mark analyses were able to identify genes associated with T cell differentiation and CART cell expansion that were not identified by RNA sequencing. Additionally, histone mark analyses were able to distinguish CART products that were associated with higher CART cell counts in patient blood after infusion. This study highlights the potential of histone mark analyses to improve outcomes in CART immunotherapy. [Extracted from the article]